Skip to main content
padlock icon - secure page this page is secure

A Novel Fullerene-Based Drug Delivery System Delivering Doxorubicin for Potential Lung Cancer Therapy

Buy Article:

$106.51 + tax (Refund Policy)

We developed an attractive method to prepare a fullerene-based (C82) drug delivery system modified with doxorubicin (DOXO) and cyclic RGD motif (DOXO-C82-cRGD) for potential clinic use treating solid tumors, lung cancers. The DOXO-C82-cRGD nanoparticles with a diameter of ~1.7 nm were prepared and the chemical structure was confirmed with MALDI-TOF, dynamic light scattering (DLS), and X-ray photoelectron spectroscopy (XPS). The DOXO-C82-cRGD nanoparticles showed great stability in phosphate buffer solution (PBS) and were also stable in low concentration of thiols (20 μM). On the contrary, the high concentration of thiols (10 mM) remarkably enhanced the deconjugation of DOXO-C82-cRGD. The in vitro results demonstrated that DOXO-C82-cRGD nanoparticles showed great preferential cellular uptake in non-small lung cancer cells as compared with DOXO-C82 and particularly, DOXO. Moreover, the cell viability results suggested that DOXO-C82-cRGD had significant cytotoxicity to cells at low dose. Apparently, the DOXO-C82-cRGD nanoparticles showed strong in vitro anti-tumor ability. Our study certainly provide a novel drug delivery system for preparing DOXO-contained vehicles for solid tumor therapy in clinic.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: C82; Doxorubicin; Drug Delivery; Lung Cancers

Document Type: Research Article

Affiliations: College of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China

Publication date: August 1, 2017

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more